By Fineline Cube 
China-based Sino Biopharmaceutical Limited (HKG: 1177) announced its financial results for the first half of 2025. The company reported revenue of ¥17.57 billion, representing a year-on-year increase of 10.7%. Net profit attributable to owners of the parent from continuing operations soared by 140.2% to ¥3.39 billion. Adjusted net profit attributable to owners of the parent grew by 101.1% to ¥3.09 billion. Notably, revenue from innovative products and their share of total revenue saw significant growth, now accounting for 44.4% of the total.
R&D and Innovation
During the reporting period, Sino Biopharmaceutical continued to deepen its focus on R&D for innovative drugs. R&D expenses for these products constituted 78% of the total, reflecting the company’s commitment to optimizing its investment structure. Revenue from innovative products reached ¥7.8 billion, marking a robust year-on-year increase of 27.2%.
Regulatory Approvals
Over the past two years, the company has received approval for 11 innovative products, which have been a core driver of its performance growth. In 2025, several innovative products received approval, including Meloxicam, China’s first and the world’s only long-acting injectable NSAID for pain relief, and N01, China’s first approved domestic recombinant human coagulation factor VIIa for injection.-Fineline Info & Tech